Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Colorectal cancer AND EGFR, mENA, 1956, ENSG00000146648, P00533, ERBB1, ERBB AND Clinical Outcome
128 results:

  • 1. Feasibility of [
    Bae SW; Wang J; Georgiou DK; Wen X; Cohen AS; Geng L; Tantawy MN; Manning HC
    Tomography; 2023 Feb; 9(2):497-508. PubMed ID: 36961000
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Combined PD-1, BRAF and MEK inhibition in BRAF
    Tian J; Chen JH; Chao SX; Pelka K; Giannakis M; Hess J; Burke K; Jorgji V; Sindurakar P; Braverman J; Mehta A; Oka T; Huang M; Lieb D; Spurrell M; Allen JN; Abrams TA; Clark JW; Enzinger AC; Enzinger PC; Klempner SJ; McCleary NJ; Meyerhardt JA; Ryan DP; Yurgelun MB; Kanter K; Van Seventer EE; Baiev I; Chi G; Jarnagin J; Bradford WB; Wong E; Michel AG; Fetter IJ; Siravegna G; Gemma AJ; Sharpe A; Demehri S; Leary R; Campbell CD; Yilmaz O; Getz GA; Parikh AR; Hacohen N; Corcoran RB
    Nat Med; 2023 Feb; 29(2):458-466. PubMed ID: 36702949
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. EPLIN, a Putative Tumour Suppressor in colorectal cancer, Implications in Drug Resistance.
    Zeng J; Sanders AJ; Ye L; Hargest R; Ruge F; Jiang WG
    Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499558
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Liquid Biopsy Detects Early Molecular Response and Predicts Benefit to First-Line Chemotherapy plus Cetuximab in Metastatic colorectal cancer: PLATFORM-B Study.
    Vidal J; Fernández-Rodríguez MC; Casadevall D; García-Alfonso P; Páez D; Guix M; Alonso V; Cano MT; Santos C; Durán G; Elez E; Manzano JL; Garcia-Carbonero R; Ferreiro R; Losa F; Pineda E; Sastre J; Rivera F; Bellosillo B; Tabernero J; Aranda E; Salazar R; Montagut C;
    Clin Cancer Res; 2023 Jan; 29(2):379-388. PubMed ID: 36074154
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience.
    Boccaccino A; Borelli B; Intini R; Antista M; Bensi M; Rossini D; Passardi A; Tamberi S; Giampieri R; Antonuzzo L; Noto L; Roviello G; Zichi C; Salati M; Puccini A; Noto C; Parisi A; Rihawi K; Persano M; Crespi V; Libertini M; Giordano M; Moretto R; Lonardi S; Cremolini C
    ESMO Open; 2022 Jun; 7(3):100506. PubMed ID: 35696748
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. A five-year follow up study of stage I-IV of rectal cancer with an emphasis on epidermal growth factor over-expression.
    Kozłowska-Geller MA; Lewitowicz P; Głuszek SZ
    Pol J Pathol; 2021; 72(2):124-129. PubMed ID: 34706519
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. A Possible Distinct Molecular Subtype (Quintuple-Wildtype) of Metastatic colorectal cancer in First-Line Anti-egfr Therapy with Cetuximab Plus FOLFIRI - Palliative Precision Therapy and a Multidisciplinary Treatment Approach: Interim Analysis of the IVOPAK II Trial with Early Results.
    Wein A; Stoehr R; Kersting S; Siebler J; Merkel S; Busse D; Wolff K; Ostermeier N; Neufert C; Vitali F; Eckstein M; Roth JP; Anhut P; Schreiner W; Uder M; Hartmann A; Neurath MF; Grützmann R
    Oncology; 2022; 100(1):1-11. PubMed ID: 34670215
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Circulating tumor DNA sequencing in colorectal cancer patients treated with first-line chemotherapy with anti-egfr.
    Lim Y; Kim S; Kang JK; Kim HP; Jang H; Han H; Kim H; Kim MJ; Lee KH; Ryoo SB; Park JW; Jeong SY; Park KJ; Kang GH; Han SW; Kim TY
    Sci Rep; 2021 Aug; 11(1):16333. PubMed ID: 34381078
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Immune checkpoints and liver resection after neoadjuvant chemotherapy including bevacizumab in patients with microsatellite-stable colorectal liver metastases.
    Stift J; Graf A; Neudert B; Herac M; Woeran K; Tamandl D; Laengle J; Schwarz C; Wrba F; Kaczirek K; Stremitzer S
    HPB (Oxford); 2022 Jan; 24(1):40-46. PubMed ID: 34158230
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic colorectal cancer Receiving Irinotecan and Cetuximab as Later Line Treatment.
    Ziranu P; Lai E; Schirripa M; Puzzoni M; Persano M; Pretta A; Munari G; Liscia N; Pusceddu V; Loupakis F; Demurtas L; Libertini M; Mariani S; Migliari M; Dubois M; Giampieri R; Sotgiu G; Dei Tos AP; Lonardi S; Zaniboni A; Fassan M; Scartozzi M
    Target Oncol; 2021 Jul; 16(4):517-527. PubMed ID: 33970400
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Improving selection of patients with metastatic colorectal cancer to benefit from cetuximab based on KIR genotypes.
    Manzanares-Martin B; Cebrián Aranda A; Del Puerto-Nevado L; González R; Solanes S; Gómez-España MA; García-Foncillas J; Aranda E
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33833048
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Comprehensive functional genomic analyses link APC somatic mutation and mRNA-miRNA networks to the clinical outcome of stage-III colorectal cancer patients.
    Chiang SF; Huang HH; Tsai WS; Chin-Ming Tan B; Yang CY; Huang PJ; Yi-Feng Chang I; Lin J; Lu PS; Chin E; Liu YH; Yu JS; Chiang JM; Hung HY; You JF; Liu H
    Biomed J; 2022 Apr; 45(2):347-360. PubMed ID: 35550340
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Multiverse of immune microenvironment in metastatic colorectal cancer.
    Van den Eynde M; Mlecnik B; Bindea G; Galon J
    Oncoimmunology; 2020 Sep; 9(1):1824316. PubMed ID: 33457100
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Expression and function of epithelial cell adhesion molecule EpCAM: where are we after 40 years?
    Gires O; Pan M; Schinke H; Canis M; Baeuerle PA
    Cancer Metastasis Rev; 2020 Sep; 39(3):969-987. PubMed ID: 32507912
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. HER4 promotes the progression of colorectal cancer by promoting epithelial‑mesenchymal transition.
    Jia X; Wang H; Li Z; Yan J; Guo Y; Zhao W; Gao L; Wang B; Jia Y
    Mol Med Rep; 2020 Apr; 21(4):1779-1788. PubMed ID: 32319604
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. The role of miRNA -31-3p and miR-31-5p in the anti-egfr treatment efficacy of wild-type K-RAS metastatic colorectal cancer. Is it really the next best thing in miRNAs?
    Sur D; Cainap C; Burz C; Havasi A; Chis IC; Vlad C; Milosevic V; Balacescu O; Irimie A
    J BUON; 2019; 24(5):1739-1746. PubMed ID: 31786833
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. RasGRP1 is a potential biomarker to stratify anti-egfr therapy response in colorectal cancer.
    Gbenedio OM; Bonnans C; Grun D; Wang CY; Hatch AJ; Mahoney MR; Barras D; Matli M; Miao Y; Garcia KC; Tejpar S; Delorenzi M; Venook AP; Nixon AB; Warren RS; Roose JP; Depeille P
    JCI Insight; 2019 Jun; 5(15):. PubMed ID: 31237864
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. clinical Significance of BRAF Non-V600E Mutations in colorectal cancer: A Retrospective Study of Two Institutions.
    Shimada Y; Tajima Y; Nagahashi M; Ichikawa H; Oyanagi H; Okuda S; Takabe K; Wakai T
    J Surg Res; 2018 Dec; 232():72-81. PubMed ID: 30463788
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. AZ304, a novel dual BRAF inhibitor, exerts anti-tumour effects in colorectal cancer independently of BRAF genetic status.
    Ma R; Xu L; Qu X; Che X; Zhang Y; Fan Y; Li C; Guo T; Hou K; Hu X; Drew L; Shen M; Cheung T; Liu Y
    Br J Cancer; 2018 May; 118(11):1453-1463. PubMed ID: 29755114
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Anal squamous cell carcinoma - State of the art management and future perspectives.
    Martin D; Balermpas P; Winkelmann R; Rödel F; Rödel C; Fokas E
    Cancer Treat Rev; 2018 Apr; 65():11-21. PubMed ID: 29494827
    [TBL] [Abstract] [Full Text] [Related]  


    of 7.